Cancel

Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape

Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now. STATEMENT OF NEED Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana...
i3 Health

Improving Outcomes in Hodgkin Lymphoma

This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now. STATEMENT OF NEED Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ...
i3 Health

Diagnosis and Evidence-Based Management of T-Cell Lymphoma

STATEMENT OF NEED T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic...
i3 Health

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLL

Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including BTK inhi...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC,

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Patient Selection

Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC,

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Aligning Patient and Provider Goals

Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the CLL Society (CLLS) and the Leukemia & Lymphoma Society (LLS).

Follicular Lymphoma: Answers to Important Nursing Questions

Target Audience This activity is designed to meet the educational needs of oncology nurses, nurse practitioners and navigators engaged in the care of patients with follicular lymphoma. Program Overview Advances in the treatment of FL have led to the approval of two novel agents as well as updates to clinical practice guidelines. Oncology nursing professionals have unique and often long-standing relationships with their FL patients and are trusted sources of information and support. Th...
American Academy of CME, Inc.

Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC

This interactive digital activity combines animated slides and expert video commentary on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence to enhance the implementation of precision medicine in the care of patients with EGFR-mutant NSCLC. Through this education, learners explore best practices for EGFR mutation testing, application of clinical trial data to treatment selection, and the role of concurrent mutations in the prognos...
ACHL

Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management

B-cell non-Hodgkin lymphoma management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy—the majority of which do so because of adverse events (AEs)—and data suggest that the management of AEs is not consistent with recommendations. Moreover...
Lymphoma Research Foundation, RedMedEd, and Rutgers Biomedical and Health Sciences

Updates in Mantle Cell Lymphoma

Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now. STATEMENT OF NEED Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin ly...
i3 Health

Treatment Advances in Waldenstrom Macroglobulinemia

In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now. STATEMENT OF NEED Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphop...
i3 Health

Ace the Case: Disease Progression in a 65-Year-Old Man With Previously Treated Mantle Cell Lymphoma

This activity utilizes a case study to discuss treatment options for an older patient with relapsed mantle cell lymphoma (MCL).
Postgraduate Institute for Medicine

CAR-T Therapy: What’s in the CARds? – Module 1

Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides an overview of CAR T-cell development, available CAR T-cell products for blood cancers, and important side effects of CAR T-cell therapy. Learning Objective Upon completion of this activity, participants should be better able to: ...
The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2

Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides an overview of important genetic mutations in acute myeloid leukemia and recent therapeutic advances. Learning Objective Upon completion of this activity, participants should be better able to: Identify the impact of minimal resid...
The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3

Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes. Learning Objective Upon completion of this activity, participants should be better able to: Sum...
The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Novel Therapeutic Strategies in Myeloma – Module 4

Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides an overview of recent therapeutic advances for patients with newly diagnosed or relapsed multiple myeloma and the mechanisms by which novel therapies work. Learning Objective Upon completion of this activity, participants should be b...
The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

COVID-19, Vaccinations, and Blood Cancer Patients: The LLS Registry and Q&A – Module 5

Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides a review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination in patients with blood cancer and audience Q&A. Learning Objective Upon completion of this activity, participants should be better able ...
The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Key Questions Answered in the Management of Follicular Lymphoma

Advances in the treatment of FL have led to the approval of two novel agents and updates to clinical practice guidelines. Nurses have unique and often long-standing relationships with their patients who have FL and are trusted sources of information and support. Oncology nurses who care for patients with FL should be aware of treatment guideline changes and their impact on clinical practice. Recently approved novel medications are associated with unique toxicities that differ from standard che...
American Academy of CME

Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy

TARGET AUDIENCE: Hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with LBCL. PROGRAM OVERVIEW: In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive c...
The Annenberg Center for Health Sciences at Eisenhower

Targeting Large B-Cell Lymphoma: Advances in Treatment

TARGET AUDIENCE: This activity is designed to meet the educational needs of hematology/oncology physicians, nurse practitioners, nurses, PAs, pharmacists, and other healthcare professionals who care for patients with DLBCL. PROGRAM OVERVIEW: The archived version of an interactive nationwide webinar focused on advances in the management of patients with diffuse large B-cell lymphoma (DLBCL). LEARNING OBJECTIVES: Upon completion of this activity, participants should be better able to: -...
National Jewish Health and Catamount Medical Education

New Perspectives in the Management of Marginal Zone Lymphoma

STATEMENT OF NEED Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from memory B lymphocytes located in the marginal zone of secondary lymphoid follicles present in the spleen; and nodal MZL, which originates in...
i3 Health

2022 Pan Pacific Lymphoma Conference " Expert Insights

Target Audience The 2022 Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. This enduring activity will benefit members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists. Learning Objectives Upon completion of this activity, participants should be bett...
The University of Nebraska Medical Center

Podium to Practice: Clinical Integration of New Advances in the Treatment of Patients with B-Cell Malignancies Updates from ASCO and EHA

Program Overview This activity aims to provide healthcare professionals who treat patients with B-cell malignancies with an update of recently presented clinical trial data from the ASCO and EHA Annual Meetings that will impact the care of these patients in 2022 and beyond. Target Audience The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patient...
The University of Nebraska Medical Center and Bio Ascend

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map